Transforming cancer treatment and advancing new therapies through empowered science

Corporate Profile

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.

The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs designed to address the unmet medical needs of people with cancer, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME. Seattle Genetics’ ADC technology is employed by a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. Across both internal and collaborator programs, there are 25 ADCs in clinical development using our proprietary approach to empowering antibodies.

Download Documentation  Corporate Fact Sheet
Download Documentation  2013 Annual Report
Download Documentation  2014 Proxy Statement
Investor Contact
Peggy Pinkston
Senior Director, Corporate Communications
PHONE: (425) 527-4160
FAX: (425) 527-4001
EMAIL: ppinkston@seagen.com

Media Contact
Tricia Larson
Director, Public Relations
PHONE: 425-527-4180
EMAIL: tlarson@seagen.com
Stock Quote
SGEN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$36.44
Change (%) Stock is Down 0.35 (0.95%)
Volume389,460
Data as of 11/28/14 1:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >
DateTitle 
11/18/14Seattle Genetics Names New General Counsel and Executive Vice President, Legal Affairs
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 18, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Jean I. Liu, as General Counsel, Executive Vice President, Legal Affairs and Corporate Secretary. Ms. Liu brings more than 20 years of professional experience advising pharmaceutical and biotechnology companies on a broad range of corporate, intellectual property, compliance and general legal matters. She will report to Clay Siegall, ... 
Printer Friendly Version
11/07/14Seattle Genetics to Present Clinical Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
Positive Phase 3 AETHERA Clinical Trial Results to be Featured in an Oral Presentation Fifteen ADCETRIS Data Presentations, Including Seven Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Positive Malignancies Five Additional Data Presentations from Proprietary and Collaborator ADCs BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 7, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) tod... 
Printer Friendly Version
11/04/14Seattle Genetics to Present at Credit Suisse Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 4, 2014-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 11, 2014, at 8:30 a.m. Mountain Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section. About Seattle Genetics Seattle Genetics ... 
Printer Friendly Version
10/30/14Seattle Genetics Reports Third Quarter 2014 Financial Results
-Total Third Quarter Revenues of $75.9 Million, Including $48.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Product Sales- -ADCETRIS 2014 Net Sales Guidance Increased to a Range of $172 Million to $177 Million- -ASH Annual Meeting to Feature 18 Abstracts on ADCETRIS and Antibody-Drug Conjugate Pipeline Programs, Including an Oral Presentation on the Phase 3 AETHERA Trial- -Conference Call Today at ... 
Printer Friendly Version
10/14/14Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial Results on October 30, 2014
BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 14, 2014-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its third quarter 2014 financial results on Thursday, October 30, 2014 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.